Gelonghui, May 29丨Huajian Healthcare (01931.HK) announced that on May 29, 2024, the company signed a non-legally binding memorandum of understanding with a potential partner (“potential partner”) in China on investment cooperation matters.

Established in 2011, the potential partner is an in vitro diagnostic enterprise with chemiluminescence technology and products as the core. Potential partners have established a chemiluminescence technology platform based on alkaline phosphatase. The chemiluminescence reagent test function list includes multiple sets of tests for sex hormones, tumor markers, thyroid function hormones, renal function tests, bone metabolism, myocardial markers, high blood pressure, liver fibrosis, and pre-operative eight items. Potential partners have many years of rich R&D experience and continuous R&D capabilities. Especially in terms of reagents, years of accumulation have a certain comparative advantage.

According to the proposed cooperation, the company will provide subsequent operating capital for potential partners. According to the relevant regulations of the State Drug Administration, the company's wholly-owned subsidiary will sell potential partner products, eliminate complicated steps such as product re-registration, approval, and adaptation, and use the advantages of its mature sales pipeline to bring potential partner products to the market.

After the capital increase is completed, the company will use the company's capital, own brand and sales team advantages to support potential partner biotechnology project product research and development and optimize the company's product structure. In line with in vitro diagnostic (IVD) market trends, the company uses its own sales channels to promote potential partner biological products, and strive to rapidly expand commercial channels to achieve the company's performance development.